Furthermore, the strong correlation of cyclin D1 overexpression with mutated KRAS that we report in human NSCLC tumours, underscores the attractivity of CDK4/cyclin D as a pharmacological target for development of anticancer therapeutics, in particular in KRAS-mutant lung cancer, which has been described to be particularly dependent on CDK4 8. Here, CDK4 is linked to lung carcinoma.